ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
Diseases Related With Impairments In Kynurenine Pathway Metabolism And Therapeutic Approaches: Review
Dr. Fatma TAYFUN,a Dr. Gülay ŞADANa
aFarmakoloji AD, Akdeniz Üniversitesi Tıp Fakültesi, ANTALYA
In mammals, the vast majority of dietary tryptophan is metabolized via the kynurenine pathway (KP), which is initiated by the oxidative opening of the indole ring and eventually produces the ubiquitous enzyme cofactor nicotinamide adenine dinucleotide (NAD+). Several neuroactive intermediates are yielded with the degradation of triptophan by this pathway, including the free radical generator 3-hydroxykynurenine, the excitotoxic N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid, and the NMDA and 7-nicotinic acetylcholine receptor antagonist kynurenic acid. The kynurenine pathway may play a role in certain physiological functions such as behaviour, sleep, thermoregulation and pregnancy. Furthermore, the kynurenine pathway may be involved in the pathogenesis of a number of cerebral diseases including the AIDS dementia complex, Huntington’s disease, Alzheimer, epilepsy, Down syndrome, septicemia-related encephalopathy, toxoplasmosis, malaria, and certain inflammatory brain diseases, as well as in traumatic brain injury. New pharmacological agents designed to manipulate concentrations of kynurenine pathway intermediates may prove to be new therapeutic vectors in the treatment of these disorders.Keywords: Kynurenine, enyzme inhibitorsTurkiye Klinikleri J Med Sci 2005, 25:93-99
|
|
|
|
|
